Person: ATASOY, BESTE MELEK
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
ATASOY
First Name
BESTE MELEK
Name
9 results
Search Results
Now showing 1 - 9 of 9
Publication Metadata only Baş-Boyun Kanserli Hastalarda Radyoterapiyle İlişkili Erken ve Geç Etkilerin Yönetimi(Türkiye Klinikleri, 2022-01-01) ATASOY, BESTE MELEK; GÜL D., ÜÇÜNCÜ KEFELİ A., ATASOY B. M.Radyoterapi baş-boyun kanserlerinin tedavisinde ana modalitelerden biridir. Gelişen teknoloji tümöre yüksek doz uygulamayı sağlarken risk altındaki organları daha iyi korumaya yardımcı olur. Buna rağmen bu bölgenin kompleks anatomisi birden fazla hedef dışı organın fonksiyonel olarak etkilenmesine ve hastanın hayat kalitesinin bozulmasına neden olabilmektedir. Kaçınılmaz olan erken ve geç yan etkilerin sıklık ve şiddetinin azaltılabilmesi iyi bir tedavi planlamasıyla başlar; bir dizi erken müdahale ve iyi bir takiple devam eder. Tedaviye bağlı yan etkilerin yönetimi en az hastalık kontrolü kadar önemlidir. Bu makalede baş-boyun kanserlerinde radyoterapiye bağlı başlıca erken ve geç yan etkilerin yönetimi güncel literatür ışığında incelenmiştir. Anahtar Kelimeler: Baş-boyun kanserleri; radyoterapi; yan etkilerPublication Metadata only Sağlıkta yapay zekânın etik yönü(Türkiye Klinikleri, 2022-01-01) ATASOY, BESTE MELEK; SERT, GÜRKAN; ATASOY B. M., ÜÇÜNCÜ KEFELİ A., SERT G.Publication Metadata only Prognostic factors in progressive high-grade glial tumors treated with systemic approach: A single center experience(SAGE PUBLICATIONS LTD, 2021) ATASOY, BESTE MELEK; Alan, Ozkan; Telli, Tugba Akin; Tuylu, Tugba Basoglu; Arikan, Rukiye; Demircan, Nazim Can; Ercelep, Ozlem; Kaya, Serap; Babacan, Nalan Akgul; Atasoy, Beste M.; Bozkurt, Suheyla; Bayri, Yasar; Gul, Dilek; Ekinci, Gazanfer; Ziyal, Ibrahim; Dane, Faysal; Yumuk, P. FuldenPurpose Malignant high-grade gliomas are the most common and aggressive type of primary brain tumor, and the prognosis is generally extremely poor. In this retrospective study, we analyzed the outcome of systemic treatment in recurrent high-grade glioma patients and the impact of prognostic factors on survivals. Methods Data from 114 patients with recurrent high-grade glioma who received systemic treatment and followed in our clinic between 2012 and 2018 were retrospectively analyzed. Eastern Cooperative Oncology Group (ECOG) performance status, age, gender, histology, type of surgical resection, side effects after systemic treatment (deep vein thrombosis, hypertension, proteinuria), IDH1 and alpha thalassemia/mental retardation syndrome X-linked (ATRX) mutation status were investigated as prognostic factors for progression-free survival and overall survival. Results At the time of diagnosis, the median age was 48 (17-77) and 68% of the patients were male. Most common pathologic subtype was glioblastoma multiforme (68%). Median follow-up duration was 9.1 months (1-68 months). Median progression-free survival and overall survival were 6.2 months and 8 months, respectively. In multivariate analysis, ECOG PS, deep venous thrombosis and the presence of ATRX and IDH1 mutation were found to be independent prognostic factors for progression-free survival (p < 0.05) and, ECOG PS, the presence of ATRX and IDH1 mutation for overall survival (p < 0.05). Conclusion Our study is real life data and the median progression-free survival and overall survival rates are similar to the literature. We have found ECOG PS, presence of ATRX and IDH1 mutation to be independent prognostic factors for both progression-free survival and overall survival.Publication Metadata only The role of radiotherapy in intracranial hemangiopericytoma: TROD CNS group study 07-008(2022-05-01) ATASOY, BESTE MELEK; Kaydihan N., Guney Y., Yazici G., Erpolat P., Kamer S., Atasoy B. M., Aslan D., ATALAR B., Demircioglu F., Dincbas F. O., et al.Publication Metadata only Prognostic value of modified Glasgow prognostic score in recurrent high-grade glial tumors treated with systemic treatment(ELSEVIER, 2020) ATASOY, BESTE MELEK; Alan, Ozkan; Telli, Tugba Akin; Basoglu, Tugba; Arikan, Rukiye; Demircan, Nazim Can; Ercelep, Ozlem; Bozkurt, Suheyla; Atasoy, Beste Melek; Dane, Faysal; Yumuk, Perran FuldenObjectives: Malignant high-grade gliomas are the most common and aggressive type of primary brain tumor. We aimed to evaluate the prognostic value of modified Glasgow Prognostic Score (mGPS), which is combination of C-reactive protein (CRP) and albumin, in recurrent high-grade glioma patients treated with systemic treatment. Patients and Methods: Data of 85 patients with recurrent high-grade glioma who received systemic treatment and followed in our clinic between 2012 and 2018 was retrospectively collected and analyzed. Patients were grouped according to mGPS criteria: mGPS-0: CRP 10 mg/L and albumin 3.5 g/dL or CRP 10 mg/L and albumin > 3.5 g/dL; and mGPS-2: CRP > 10 mg/L and albumin < 3.5 mg/L. We investigated the prognostic role of mGPS groups, mutations and survival outcomes. Results: There were 42 (49.4 %), 25 (29.6 %), and 18 (21 %) patients in mGPS-0, mGPS-1, and mGPS-2 groups, respectively. Median follow-up duration was 10 months (1-70 months). Median OS was 8.1 months. According to mGPS-0,-1 and-2; median OS was 13.8 months, 7.3 months and 3.6 months respectively (p = 0.003). mGPS, ATRX and IDH-1 mutation status, and ECOG PS were found to be independent prognostic factors for OS. Conclusion: In our study, mGPS was found to be an independent prognostic factor in patients with recurrent high-grade gliomas. If validated, mGPS can be used as an objective, easily calculated, cheap, and readily available prognostic model in routine practice.Publication Metadata only Anxiety and depression level and body appreciation of breast cancer patients who had oncology physician and nurse led education during postoperative radiotherapy(2020-10-17) ÖZGEN, ZERRİN; YANARTAŞ, ÖMER; ATASOY, BESTE MELEK; Çankaya G., Özgen Z., Korkmaz A., Yanartaş Ö., Atasoy B. M.OP-02 Anxiety and depression level and body appreciation of breast cancer patients who had oncology physician and nurse led education during postoperative radiotherapy Gul Cankaya, Zerrin Ozgen, Ayse Korkmaz, Omer Yanartas, Beste Melek Atasoy Department Of Radiation Oncology Marmara University Pendik Training Hospital Istanbul Turkey INTRODUCTION: In this study, we have investigated effect of education on anxiety and depression levels and body perception of breast cancer patients during postoperative radiotherapy (RT) led by physicians and oncology nurse. MATERIAL-METHODS: Ethical approval was obtained from institutional ethical committee. In this prospective study we have enrolled 50 patients with written consent who were operated and had indication for RT (n = 50). Hospital Anxiety and Depression Scale (HAD-A1 and HAD-D1) and Body Appreciation Scale (BAS-1) were applied to patients after first examination. Then the patients had education on these topics: steps of radiotherapy, side effects and precautions, simulation, main points in simulation, deep breathing for patients operated on the left chest, significance of crunches, doing deep breathing exercise, the factors in skin care during RT, lymphedema, protection from lymphedema, making a breast self-examination, importance of inspection, importance of preventive health screenings and its intervals, importance of nutrition and activity in breast cancer. In line with the demands of patients, they had dietician and psychiatry support. However, radiotherapy skin reactions that may develop on the patient\"s skin during treatment was followed up regularly and complaints were answered. HAD (HAD-A2, HAD-D2) and BAS (BAS-2) were applied again after RT completed. RESULTS: Mean HAD-A1 was 4.9 (0 -15) SD 0.36, whereas HAD-A2 was 1.6 (0-5) SD 1.56. HAD-D1 resulted with average 3.7 (0-16) SD at 3.89 and HAD-D2 with mean 1.08 (0-5) SD 1.17. BAS-1 resulted mean 44.50 (33-50) SD 4.67 and BAS-2 with 46.68 (36-50) SD 3.74. HAD-A scores for 39 patients had decreased with only one increased and 10 remained same. Comparison of anxiety before and after treatment were made by Wilcoxon test; statistically it was found decreased significantly (p <0.05). HAD-D scores of 5 patients over 11 points returned to normal in second test. While HAD-D scores of 35 patients had decrement, 3 patients had mild increase and 12 remained stable. There was a statistically significant improvement in the depression scale (p<0.05). After the treatment, BAS scores had statistically significant increase (p<0.05). DISCUSSION: Anxiety in 3 patients and depression in 5 patients were high but regressed to normal. BAS scores had increment. Patients having regularly information had decreased anxiety and depression scales. It has been found increase in BBS scores. CONCLUSION: HAD-A, HAD-D and BAS scales helped monitoring positive effect of information on patients on RT. Keywords: Breast cancer, Radiotherapy, Hospital anxiety depression scale, Body appreciation scale, Breast cancer education nurse.Publication Metadata only Long-term neuromusculoskeletal side effects and quality of life in nasopharyngeal cancer patients receiving radiochemotherapy(SPRINGER, 2020) ATASOY, BESTE MELEK; Kefeli, Aysegul Ucuncu; Sanal-Toprak, Canan; Asedov, Ruslan; Ozen, Zeynep; Akyuz, Gulseren; Dane, Faysal; Atasoy, Beste M.Aim In this study, we aimed to evaluate the neuromusculoskeletal late side effects and their impact on the quality of life of patients with nasopharyngeal carcinoma treated with radiochemotherapy. Patients and methods Twenty-seven patients were included. The mean follow-up was 61 months (range, 18-111 months). The median external radiotherapy dose applied to the nasopharynx and primary tumor was 70 Gy (range, 61-73 Gy). The mean dose received by the temporomandibular joint in the dose-volume histograms of these patients was 60.7 Gy. The maximal doses of the muscles responsible for cervical motion in different ranges were greater than 60 Gy, and the mean doses were greater than 40 Gy in the muscle groups, except for the extensor muscles. Results Two patients had brachial plexus involvement, while 89% of the patients had restriction in flexion and extension movements. Of the patients, 52% had trismus. There was a significant correlation between extension restriction and general heath score and the physical subscale of the quality-of-life questionnaire (p = 0.01). There was also a correlation between trismus and pain killer usage (p = 0.004). Conclusion This is the first study to analyze long-term muscle and nerve toxicity and their correlation between doses in nasopharyngeal cancer patients following radiochemotherapy. Despite the advances in radiotherapy techniques, it is necessary to pay attention to the doses of the nerves and muscles for late effects.Publication Metadata only Rechallenge with dabrafenib plus trametinib in anaplastic thyroid cancer: A case report and review of literature(MOSBY-ELSEVIER, 2021) ATASOY, BESTE MELEK; Arikan, Rukiye; Telli, Tugba Akin; Demircan, Nazim Can; Baoglu, Tugba; Ercelep, Ozlem; Atasoy, Beste Melek; ozguven, Salih; Dane, Faysal; Yumuk, Perran FuldenIntroduction: Anaplastic thyroid carcinoma (ATC) is a highly aggressive, undifferentiated rare tumor. Median overall survival is usually between 8 and10 months, with a 1-year survival rate of 20%. Conventional anthracycline based chemotherapy regimens demonstrate low response rates with short duration. Novel therapeutic agents including BRAF and MEK inhibitors based on the molecular landscape of ATC have been investigated. Case presentation: We herein report the rechallenge of a 52-year-old ATC patient with BRAF V600E mutation with dabrafenib plus trametinib. She presented with recurrent and progressive disease despite surgery, radiation therapy, 3 different chemotherapy regimens, and combination of dabrafenib-trametinib in different settings. She was rechallenged with dabrafenib-trametinib, and had a good response. Conclusion: To our knowledge, this is the first ATC case who responded to dabrafenib-trametinib rechallenge, reported in the literature. We want to emphasize that combination of dabrafenib and trametinib might be a good choice for resistant locoregional and metastatic ATC patients with BRAF V600E mutation, particularly in whom rapid clinical response is urgently needed. Moreover, rechallenge with this combination should be kept in mind in selected cases. (c) 2020 Elsevier Inc. All rights reserved.Publication Metadata only Radyason onkolojisinde klinik araştırmalarda etik(Türkiye Klinikleri, 2022-01-01) ATASOY, BESTE MELEK; ÜÇÜNCÜ KEFELİ A., ATASOY B. M.